Control-IQ Technology in the Real World

Lars Mueller,* Alexandra Constantin, Harsimran Singh, Steph Habif †


To examine real-world glycemic outcomes in a sample of early adopters of Control-IQ® technology on the t:slim X2™ insulin pump.


Real-world t:connect® web application data was retrospectively analyzed of 1,659 individuals with type 1 and type 2 diabetes who had recently started using Control-IQ technology and uploaded at least 30 days of pre- and post-Control-IQ software update usage data to the t:connect web application from Tandem Diabetes Care by March 11, 2020.


After 30 days of using Control-IQ technology, participants showed a 10% increase in median sensor time in range (TIR), from 68% to 78%. Improvements in sensor TIR were consistent across age groups. Sensor time >180 mg/dL showed a 10% decrease after 30 days of Control-IQ technology and 0.1% decrease of sensor time <70 mg/dL. Overall, participants showed a 96% median time in closed-loop automation.

Percentage of Time Sensor Spent in Range

Percentage of Time Sensor Spent in Range


Real-world data from early adopters of Control-IQ technology demonstrate significantly improved sensor TIR after 30 days of using this technology without increasing hypoglycemia (sensor time <70 mg/dL). TIR improvements based on reduced time in hypoglycemia and hyperglycemia, if maintained long-term, can help reduce the risk of diabetes-related complications.